Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis
- 1 November 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (11), 8779-8790
- https://doi.org/10.1002/jcp.29721
Abstract
Since in cell therapy, there are always concerns about immune rejection, genetic disability, and malignancies, special attention has been paid to extracellular vesicles (EVs) which are secreted by mesenchymal stem cells (MSCs). In the present study, we assessed and compared the therapeutic effects of human adipose-derived mesenchymal stem cells (hADSC) and hADSC-EVs from adipose tissue on experimental autoimmune encephalomyelitis (EAE). After induction of EAE in C57Bl/6 mice, they were treated with hADSCs, hADSC-EVs, or vehicle intravenously. The clinical score of all mice was recorded every other day. Mice were killed at Day 30 and splenocytes were isolated for proliferation assay and determination of the frequency of Treg cells by flow cytometry. Leukocyte infiltration by hematoxylin and eosin, percentages of demyelination areas by luxol fast blue, and mean fluorescence intensity of oligodendrocyte transcription factor 2 (OLIG2) and myelin basic protein (MBP) by immunohistochemistry were assessed in the spinal cord. Our results showed that the maximum mean clinical score and myelin oligodendrocyte glycoprotein-induced proliferation of splenocytes in hADSC- and hADSC-EV-treated mice were significantly lower than the control mice (p < .05). We also demonstrated that the frequency of CD4(+)CD25(+)Foxp3(+) cells was significantly higher in the spleen of hADSC-treated mice than EAE control mice (p = .023). The inflammation score and the percentages of demyelination areas in hADSC- and hADSC-EV-treated groups significantly declined compared with the untreated control group (p < .05). We also showed that there was no significant difference in MFI of MBP and OLIG2 in the spinal cord of studied groups. Overall, we suggest that intravenous administration of hADSC-EVs attenuates the induced EAE through diminishing proliferative potency of T cells, mean clinical score, leukocyte infiltration, and demyelination in a chronic model of multiple sclerosis.Funding Information
- Isfahan University of Medical Sciences (397346)
This publication has 47 references indexed in Scilit:
- Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosisMultiple Sclerosis Journal, 2018
- Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune UveitisScientific Reports, 2017
- Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell FunctionStem Cells International, 2017
- Diagnosis of multiple sclerosis: progress and challengesThe Lancet, 2016
- Immunoregulatory Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles on T LymphocytesCell Transplantation, 2015
- Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseasesEmerging Drugs, 2015
- Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in vitro Stimulated T CellsFrontiers in Immunology, 2014
- Microvescicles Derived from Mesenchymal Stromal Cells Are Not as Effective as Their Cellular Counterpart in the Ability to Modulate Immune Responses In VitroStem Cells and Development, 2014
- Adipose-Derived Mesenchymal Stem Cells Ameliorate Chronic Experimental Autoimmune EncephalomyelitisThe International Journal of Cell Cloning, 2009
- Stromal Cells Protect against Acute Tubular Injury via an Endocrine EffectJournal of the American Society of Nephrology, 2007